New antibody AK1967 tested in healthy men as potential shock therapy
NCT ID NCT06331884
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 study tested the safety and tolerability of a single intravenous dose of AK1967 (Procizumab) in 24 healthy male volunteers. AK1967 is an antibody that blocks a protein called DPP3, which may worsen blood pressure drops during cardiogenic shock. The study only looked at safety and how the drug moves through the body, not whether it works for shock.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AK1967 (Procizumab)
- What this could lead to
- If successful, this could pave the way for a new treatment for cardiogenic shock by blocking a protein that worsens blood pressure instability.
- What could go wrong
- This is a very early Phase 1 study in only 24 healthy men, so it does not test if the drug works for shock. Safety and dosing are the only goals, and unexpected side effects may still appear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Radboud University Medical Center
Nijmegen, Gelderland, 6525, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults